Histopathologic diagnosis of brain metastases: current trends in management and future considerations.

about

2D and 3D texture analysis to differentiate brain metastases on MR images: proceed with caution.Mechanisms and Therapy for Cancer Metastasis to the Brain.Epigenetic profiling for the molecular classification of metastatic brain tumors

P2860

Q47644564-6D71A1B4-22F6-4784-8E8D-2D05A83BB706 Q54950354-79522F16-391E-4BA7-9988-2F7BF801D4AA Q58608173-FC5DEA96-E918-4396-90AD-FC4749483530

P2860

Histopathologic diagnosis of brain metastases: current trends in management and future considerations.

Item

http://www.wikidata.org/entity/Q38791747

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Histopathologic diagnosis of b ...... ent and future considerations.

@en

type

Item

label

Histopathologic diagnosis of b ...... ent and future considerations.

@en

prefLabel

Histopathologic diagnosis of b ...... ent and future considerations.

@en

P1476

Histopathologic diagnosis of b ...... ent and future considerations.

@en

P2093

Evelyne Emery

http://www.w3.org/2001/XMLSchema#string

Guénaëlle Levallet

http://www.w3.org/2001/XMLSchema#string

Lien Bekaert

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer classification using the Immunoscore: a worldwide task force

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Systemic Immunotherapy for the Treatment of Brain Metastases

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.

Major response to imatinib mesylate in KIT-mutated melanoma.

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.

P2888

s10014-016-0275-3

P304

8-19

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10014-016-0275-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Emmanuèle Lechapt-Zalcman

Guénaëlle Levallet

P577

2016-11-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27878432

http://www.w3.org/2001/XMLSchema#string

Histopathologic diagnosis of brain metastases: current trends in management and future considerations.

about

P2860

P2860

Histopathologic diagnosis of brain metastases: current trends in management and future considerations.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698